FENC — Fennec Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $383.89m
- $342.64m
- $44.64m
Fennec Pharmaceuticals Q2 sales rise on PEDMARK demand
Fennec Pharmaceuticals Inc. expected to post earnings of 1 cent a share - Earnings Preview
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara
Fennec up on study testing expanded use of its hearing‑loss prevention drug in cancer patients
Fennec Pharma FY product sales rise 50% to record high on PEDMARK adoption
Brief: Fennec Pharmaceuticals Announces Settlement Agreement Resolving Pedmark Patent Litigation
U.S. RESEARCH ROUNDUP-Equinix, Generac Holdings, Gilead
U.S. RESEARCH ROUNDUP-Ardelyx, RPM International, Trubridge
Brief: Southpoint Capital Advisors- Southpoint Controls 2.7 Million Common Shares, 8% Of Outstanding Common Shares Of Fennec
Brief: Fennec Pharmaceuticals Announces Positive Topline Results
Brief: Fennec Pharmaceuticals Prices 4.6 MLN Common Shares At $7.50 Per Share
Fennec Pharmaceuticals Q3 product sales rise
Brief: Fennec Pharmaceuticals Announces Proposed Offering Of Common Shares
Brief: Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results
Fennec Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview
Fennec Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview